Crinetics stock price target raised to $87 from $73 at Oppenheimer

Investing.comTuesday, September 30, 2025 at 10:21:07 AM
Crinetics stock price target raised to $87 from $73 at Oppenheimer
Crinetics Pharmaceuticals has received a boost in its stock price target, now set at $87, up from $73, according to Oppenheimer. This increase reflects growing confidence in the company's potential and could attract more investors, signaling a positive outlook for Crinetics in the competitive pharmaceutical market.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Oppenheimer upgrades Semtech stock to Outperform on AI and LoRa growth
PositiveFinancial Markets
Oppenheimer has upgraded Semtech's stock to 'Outperform', highlighting the company's promising growth in AI and LoRa technologies. This upgrade is significant as it reflects confidence in Semtech's ability to capitalize on emerging trends in the tech industry, particularly in the fields of artificial intelligence and low-power wide-area networks. Investors may see this as a positive signal for potential returns, making it an important development in the stock market.
Crinetics stock price target raised to $75 from $58 at Stifel on Paltusotine approval
PositiveFinancial Markets
Crinetics Pharmaceuticals has received a significant boost as Stifel has raised its stock price target from $58 to $75 following the approval of its drug, Paltusotine. This positive development not only reflects confidence in the company's future prospects but also highlights the potential impact of Paltusotine in treating conditions related to acromegaly. Investors are likely to view this as a strong endorsement, which could lead to increased interest in Crinetics' stock.
Piper Sandler maintains Overweight rating on Crinetics stock after FDA approval
PositiveFinancial Markets
Piper Sandler has reaffirmed its Overweight rating on Crinetics Pharmaceuticals following the recent FDA approval of the company's new treatment. This endorsement is significant as it reflects confidence in Crinetics' growth potential and the positive impact of the FDA's decision on its stock performance. Investors are likely to view this as a strong signal for future success, making it an important development in the biotech sector.
Latest from Financial Markets
How AI Helps a Logistics Giant Thrive During a Downturn
PositiveFinancial Markets
C.H. Robinson's CEO highlights how automation and artificial intelligence are driving the company's success, even amidst a revenue decline. This is significant as it showcases the potential of technology to enhance efficiency and profitability in challenging economic times, setting a precedent for other companies in the logistics sector.
Understanding Index Funds vs. ETFs for Americans
NeutralFinancial Markets
This article explores the differences between index funds and ETFs, two popular investment options for Americans. Understanding these differences is crucial for investors looking to optimize their portfolios and make informed financial decisions. With the rise of passive investing, knowing which option suits your financial goals can significantly impact your investment strategy.
What Is the True Lifetime Cost of Owning a Home?
NeutralFinancial Markets
Understanding the true lifetime cost of owning a home is crucial for potential buyers. This article delves into various expenses beyond the mortgage, such as maintenance, taxes, and insurance, which can significantly impact financial planning. By shedding light on these hidden costs, it empowers readers to make informed decisions about homeownership, ensuring they are prepared for the long-term financial commitment involved.
Ranking the Top 10 Richest Film Producers of All Time
PositiveFinancial Markets
The latest ranking of the top 10 richest film producers highlights the immense wealth and influence of key figures in the film industry. With names like George Lucas and Steven Spielberg leading the pack, this list not only showcases their financial success but also underscores their significant contributions to cinema. Understanding who these producers are and how they amassed their fortunes can provide insights into the evolving landscape of film production and the business strategies that drive it.
Bloomin' Brands executive vice president W. Michael Healy to depart in October
NeutralFinancial Markets
W. Michael Healy, the executive vice president of Bloomin' Brands, is set to leave the company in October. His departure marks a significant change for the organization, which operates several well-known restaurant chains. This transition could impact the company's strategic direction and leadership dynamics, making it a noteworthy development for stakeholders and industry observers.
KeyBanc highlights supportive policy signals for cell and gene therapy stocks
PositiveFinancial Markets
KeyBanc has recently pointed out encouraging policy signals that could benefit cell and gene therapy stocks. This is significant because supportive regulations can lead to increased investment and innovation in these fields, potentially improving patient outcomes and advancing medical science.